Breaking News

Tuesday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Conference/Events	BofA to hold a virtual conference » 09:36 05/11/21 05/11 09:36 05/11/21 09:36 ADCT ADC Therapeutics $22.44 / -1.15 (-4.87%) , ADMS Adamas Pharmaceuticals $4.96 / -0.2 (-3.88%) , AVTR Avantor $30.48 / -0.725 (-2.32%) , CCRN Cross Country Healthcare $17.16 / +0.26 (+1.54%) , FIXX Homology Medicines $6.39 / -0.13 (-1.99%) , IMTX Immatics $10.81 / -0.77 (-6.65%) , ISRG Intuitive Surgical $835.60 / -21.9 (-2.55%) , ITCI Intra-Cellular $35.97 / +1.01 (+2.89%) , JAZZ Jazz Pharmaceuticals $176.02 / +1.35 (+0.77%) , JNJ Johnson & Johnson $170.32 / +1.68 (+1.00%) , LLY Eli Lilly $194.82 / -0.75 (-0.38%) , TVTX Travere Therapeutics $19.78 / -0.23 (-1.15%) , QGEN Qiagen $46.90 / -0.75 (-1.57%) , PTCT PTC Therapeutics $38.88 / -1.34 (-3.33%) , PHG Philips $56.39 / -1.016893 (-1.77%) , SWAV ShockWave Medical $134.82 / -12.73 (-8.63%) , RLAY Relay Therapeutics $27.69 / -1.8 (-6.10%) , ZBH Zimmer Biomet $171.99 / -0.575 (-0.33%) , WST West Pharmaceutical $333.76 / -0.36 (-0.11%) , NVRO Nevro $155.00 / -1.15 (-0.74%) , HUM Humana $470.07 / +5.45 (+1.17%) , DHR Danaher $259.10 / +0.8 (+0.31%) Bank of America Merrill… Bank of America Merrill Lynch Virtual Healthcare Conference will be held on May 11-13. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options ZBH TVTX SWAV RLAY QGEN PTCT PHG NVRO LLY JNJ JAZZ ITCI ISRG IMTX HUM FIXX DHR CCRN AVTR ADMS ADCT ZBH Zimmer Biomet $171.99 / -0.575 (-0.33%) 04/20/21 Zimmer Biomet receives FDA clearance the ROSA Partial Knee System 03/31/21 Zimmer Biomet adds Lori Winkler, Sang Yi to executive leadership team 03/19/21 Zimmer Biomet names Ivan Tornos as COO 02/22/21 Zimmer Biomet names Align Technology CDO to board TVTX Travere Therapeutics $19.78 / -0.23 (-1.15%) 02/02/21 Ligand says entitled to $5.9M milestone on Travere application submission 01/12/21 Travere Therapeutics receives orphan drug designation for sparsentan from FDA 01/11/21 Travere Therapeutics announces anticipated upcoming milestones 11/30/20 Travere Therapeutics completes patient enrollment in DUPLEX Study SWAV ShockWave Medical $134.82 / -12.73 (-8.63%) 03/30/21 ShockWave Medical provides update on U.S. launch of coronary IVL system 03/25/21 ShockWave Medical appoints Sara Toyloy to board of directors 03/22/21 ShockWave Medical to form joint venture with Genesis MedTech in China 02/16/21 ShockWave Medical receives Pre-Market Approval for intravascular lithotripsy RLAY Relay Therapeutics $27.69 / -1.8 (-6.10%) 04/16/21 Relay Therapeutics acquires ZebiAI for $85M upfront 12/14/20 Relay Therapeutics expects cash to sustain operations through 2024 12/14/20 Relay Therapeutics announces license, collaboration agreement with Genentech QGEN Qiagen $46.90 / -0.75 (-1.57%) 04/21/21 Qiagen, DiaSorin announce launch of Liaison LymeDetect Assay 04/20/21 Qiagen launches artus SARS-CoV-2 test kit 04/06/21 Qiagen launches QIAseq DIRECT SARS-CoV-2 Kit 03/29/21 Qiagen receives Emergency Use Authorization for NeuMoDx multiplex test PTCT PTC Therapeutics $38.88 / -1.34 (-3.33%) 04/15/21 PTC Therapeutics announces FIREFISH trial results at AAN virtual meeting 04/01/21 PTC Therapeutics to receive $20M commercial milestone payment from Roche 03/30/21 Roche announces European Commission approval of Evrysdi 03/30/21 PTC Therapeutics granted marketing authorization for Evrysdi from EC PHG Philips $56.39 / -1.016893 (-1.77%) 05/05/21 Philips sells ACG business to Connect America.com, terms undisclosed 04/26/21 Philips sees FY21 comparable sales up low-to-mid-single-digits 04/26/21 Philips takes EUR 250M provision for issue in sleep, respiratory care component 04/20/21 Philips reports five-year meta-analysis of Stellarex drug-coated balloon NVRO Nevro $155.00 / -1.15 (-0.74%) 04/05/21 Nevro announces publication of SENZA-PDN results in JAMA Neurology 01/19/21 Nevro announces data supporting use of HF10 therapy 12/28/20 Nevro announces FDA submission for HF10 in PDN patients 12/14/20 Boston Scientific says stipulation of dismissal filed in Nevro patent case LLY Eli Lilly $194.82 / -0.75 (-0.38%) 05/11/21 Eli Lilly, MiNA Therapeutics enter collaboration to develop drug candidates 05/04/21 AbCellera: Second antibody from pact with Eli Lilly enters trials 05/03/21 Eli Lilly announces additional $5B share repurchase program 04/27/21 Eli Lilly reports Q1 Humulin sales $321.7M, up 2% JNJ Johnson & Johnson $170.32 / +1.68 (+1.00%) 05/10/21 FDA to hold advisory committee meeting on pediatric COVID vaccine use on June 10 05/03/21 Janssen treatment of multiple myeloma granted FDA orphan designation 05/03/21 Walgreens Boots Alliance introduces mobile clinics, same-day appointments 05/03/21 Xoma earns milestone for first patient dosed in Phase 3 development program JAZZ Jazz Pharmaceuticals $176.02 / +1.35 (+0.77%) 04/23/21 GW Pharmaceuticals shareholders approve acquisition by Jazz Pharmaceuticals 04/20/21 Jazz Pharma announces results from Phase 3 study of XywavTM oral solution 04/12/21 Jazz Pharmaceuticals: FDA grants Priority Review of sNDA for Xywav 04/01/21 Lava Therapeutics appoints Karen Wilson to board of directors ITCI Intra-Cellular $35.97 / +1.01 (+2.89%) 05/03/21 Intra-Cellular announces FDA acceptance of CAPLYTA sNDAs for treating Bipolar 04/20/21 Intra-Cellular announces board of directors nominations 04/12/21 Intra-Cellular announces presentation on PDE1 inhibitor program 02/24/21 Intra-Cellular introduces new molecular entity ITI-1284 ISRG Intuitive Surgical $835.60 / -21.9 (-2.55%) 04/26/21 Intuitive Surgical appoint Monica Reed to board of directors 04/20/21 Intuitive Surgical jumps about 4% above $842 after Q1 earnings 04/20/21 Intuitive Surgical sees 'similar quarterly patterns' to 2019 on procedure trends 04/20/21 Intuitive Surgical sees FY21 procedure growth of 22%-26% IMTX Immatics $10.81 / -0.77 (-6.65%) 05/11/21 Immatics presents preclinical data for TCR bispecifics program IMA402 03/30/21 Immatics expects cash, cash equivalents to provide reach into 2023 03/17/21 Immatics presents data update on dose escalation from ACTengine programs HUM Humana $470.07 / +5.45 (+1.17%) 05/03/21 Chuy's appoints Jody Bilney to board of directors 04/28/21 Humana CEO says 'we're pleased with the strong start of the year' 04/27/21 Humana to acquire remaining interest in Kindred at Home 04/12/21 Humana reports selection by state of Ohio to serve Medicaid beneficiaries FIXX Homology Medicines $6.39 / -0.13 (-1.99%) 05/03/21 Homology Medicines presents data on in vivo nuclease-free gene editing 04/28/21 Homology Medicines announces new approach to leverage AAVHSC platform 04/14/21 Homology Medicines announces two presentations on phenylketonuria, MPS II 04/12/21 Homology Medicines announces promotion of Tim Kelly to COO DHR Danaher $259.10 / +0.8 (+0.31%) 04/28/21 Danaher EVP Weidemanis sells over 17,000 common shares 04/27/21 Danaher senior VP Lalor sells over 3,000 common shares 03/23/21 Beckman Coulter receives Emergency Use Authorization for antibody test 03/11/21 Danaher not seeing decline in Covid testing business CCRN Cross Country Healthcare $17.16 / +0.26 (+1.54%) 05/10/21 Cross Country Healthcare names Phillip Noe CIO 04/20/21 Cross Country Healthcare appoints Gerald Purgay as CMO 03/31/21 Cross Country Healthcare says DOJ indictment does not involve company AVTR Avantor $30.48 / -0.725 (-2.32%) 04/14/21 Senator Cornyn urges probe into Avantor for opioid epidemic role 04/12/21 Avantor to acquire Ritter GmbH and affiliates for EUR 890M 02/16/21 Third Point buys Upstart, exits Caesars in Q4 11/19/20 Avantor opens new biorepository facility in Europe ADMS Adamas Pharmaceuticals $4.96 / -0.2 (-3.88%) 03/29/21 Adamas publishes Gocovri data on patients with Parkinson's disease 02/01/21 Adamas Pharmaceuticals trading resumes 02/01/21 Adamas announces FDA approval for second indication for Gocovri 02/01/21 Adamas Pharmaceuticals trading halted, news pending ADCT ADC Therapeutics $22.44 / -1.15 (-4.87%) 05/05/21 ADC Therapeutics' ZYNLONTA added in NCCN Guidelines in b-cell lymphomas 04/23/21 ADC Therapeutics announces FDA approval of Zynlonta 04/23/21 ADC Therapeutics granted FDA approval for Zynlonta BLA 04/06/21 Overland ADCT BioPharma appoints Eric Koo as CEO ADCT ADMS AVTR CCRN FIXX IMTX ISRG ITCI JAZZ JNJ LLY TVTX QGEN PTCT PHG SWAV RLAY ZBH WST NVRO HUM DHR ADCT ADC Therapeutics $22.44 / -1.15 (-4.87%) 04/26/21 H.C. Wainwright ADC Therapeutics price target raised to $57 from $48 at H.C. Wainwright 03/19/21 H.C. Wainwright ADC Therapeutics price target raised to $48 from $47 at H.C. Wainwright 12/02/20 Stifel ADC Therapeutics initiated with a Hold at Stifel 10/29/20 Fly Intel: Top five analyst initiations ADMS Adamas Pharmaceuticals $4.96 / -0.2 (-3.88%) 02/02/21 H.C. Wainwright Adamas Pharmaceuticals price target raised to $12 from $10 at H.C. Wainwright 02/01/21 JMP Securities Adamas settlement brings 'robust' patent exclusivity, says JMP Securities 01/28/21 Northland Adamas Pharmaceuticals price target raised to $12.50 from $7.50 at Northland AVTR Avantor $30.48 / -0.725 (-2.32%) 04/29/21 JPMorgan Avantor price target raised to $40 from $35 at JPMorgan 04/29/21 Baird Avantor price target raised to $36 from $32 at Baird 04/29/21 Stifel Avantor upgraded to Buy after 'strong' Q1 report at Stifel 04/29/21 Stifel Avantor upgraded to Buy from Hold at Stifel CCRN Cross Country Healthcare $17.16 / +0.26 (+1.54%) 05/06/21 Benchmark Cross Country Healthcare downgraded to Hold from Buy at Benchmark 03/09/21 Barrington Barrington ups Cross Country Healthcare target to $14 after quarterly results 11/25/20 Barrington Cross Country Healthcare target raised to $12 at Barrington after Q3 results 11/23/20 BMO Capital BMO upgrades Cross Country Healthcare to Outperform on success of turnaround FIXX Homology Medicines $6.39 / -0.13 (-1.99%) 05/07/21 Oppenheimer Homology Medicines price target lowered to $24 from $27 at Oppenheimer 04/28/21 Stifel Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel 03/01/21 Stifel Homology Medicines initiated with a Hold at Stifel 03/01/21 Oppenheimer Homology Medicines loses potential source of upside, says Oppenheimer IMTX Immatics $10.81 / -0.77 (-6.65%) 03/17/21 Chardan Immatics' early TCR platform activity signals 'notable,' says Chardan 03/17/21 SVB Leerink Immatics price target raised to $26 from $17 at SVB Leerink 11/20/20 BofA Immatics initiated with a Buy at BofA 09/21/20 Goldman Sachs Immatics initiated with a Buy at Goldman Sachs ISRG Intuitive Surgical $835.60 / -21.9 (-2.55%) 04/21/21 SVB Leerink Intuitive Surgical price target raised to $860 from $825 at SVB Leerink 04/21/21 Wells Fargo Intuitive Surgical price target raised to $892 from $879 at Wells Fargo 04/21/21 Deutsche Bank Intuitive Surgical price target raised to $825 from $690 at Deutsche Bank 04/21/21 JPMorgan Intuitive Surgical price target raised to $900 from $840 at JPMorgan ITCI Intra-Cellular $35.97 / +1.01 (+2.89%) 12/29/20 Cantor Fitzgerald Intra-Cellular price target raised to $54 from $53 at Cantor Fitzgerald 12/15/20 Fly Intel: Top five analyst initiations 12/15/20 BofA Intra-Cellular initiated with a Buy at BofA 12/10/20 Fly Intel: Top five analyst initiations JAZZ Jazz Pharmaceuticals $176.02 / +1.35 (+0.77%) 04/21/21 Cantor Fitzgerald Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald 04/14/21 Stifel Jazz Pharmaceuticals price target raised to $202 from $195 at Stifel 04/06/21 RBC Capital Jazz Pharmaceuticals transferred with an Outperform at RBC Capital 04/01/21 Morgan Stanley Jazz Pharmaceuticals price target raised to $176 from $162 at Morgan Stanley JNJ Johnson & Johnson $170.32 / +1.68 (+1.00%) 05/05/21 Argus Emergent BioSolutions downgraded to Hold from Buy at Argus 04/29/21 Wells Fargo Boston Scientific price target raised to $50 from $42 at Wells Fargo 04/26/21 B. Riley B. Riley reiterates Buy on Novavax, Sell on Arcturus amid vaccine developments 04/19/21 Chardan Chardan sees J&J moving forward with Emergent if observations are minor LLY Eli Lilly $194.82 / -0.75 (-0.38%) 04/28/21 Mizuho Eli Lilly price target lowered to $216 from $228 at Mizuho 04/28/21 Barclays Eli Lilly price target lowered to $227 from $232 at Barclays 04/12/21 Benchmark Benchmark sees full FDA approval of Regeneron's REGEN-COV coming 04/06/21 JPMorgan JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug TVTX Travere Therapeutics $19.78 / -0.23 (-1.15%) 05/07/21 BMO Capital Travere Therapeutics price target lowered to $38 from $43 at BMO Capital 04/12/21 Wedbush Travere Therapeutics price target lowered to $39 from $46 at Wedbush 03/02/21 BMO Capital Travere Therapeutics price target lowered to $43 from $48 at BMO Capital 02/16/21 Barclays Travere Therapeutics assumed with an Overweight at Barclays QGEN Qiagen $46.90 / -0.75 (-1.57%) 02/19/21 Berenberg Qiagen price target raised to EUR 56 from EUR 52 at Berenberg 02/09/21 William Blair Quidel, Qiagen merger would not make sense, says William Blair 02/09/21 Wells Fargo Qiagen shares should be sold on latest merger talk, says Wells Fargo 02/09/21 Citi Merger with Qiagen would benefit Quidel, says Citi PTCT PTC Therapeutics $38.88 / -1.34 (-3.33%) 04/26/21 Credit Suisse PTC Therapeutics assumed with a Neutral at Credit Suisse 03/29/21 RBC Capital PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation 03/29/21 RBC Capital PTC Therapeutics upgraded to Sector Perform from Underperform at RBC Capital 02/26/21 Cantor Fitzgerald PTC Therapeutics price target lowered to $75 from $81 at Cantor Fitzgerald PHG Philips $56.39 / -1.016893 (-1.77%) 04/29/21 Berenberg Philips price target raised to EUR 52 from EUR 50 at Berenberg 04/28/21 Credit Suisse Philips price target raised to EUR 49 from EUR 45 at Credit Suisse 04/27/21 UBS Philips price target raised to EUR 56 from EUR 54 at UBS 03/23/21 Barclays Philips price target raised to EUR 55 from EUR 54 at Barclays SWAV ShockWave Medical $134.82 / -12.73 (-8.63%) 05/11/21 Wells Fargo ShockWave Medical price target raised to $161 from $151 at Wells Fargo 05/11/21 BofA ShockWave Medical upgraded to Buy at BofA after guidance hike 05/11/21 BofA ShockWave Medical upgraded to Buy from Neutral at BofA 05/11/21 Piper Sandler ShockWave Medical upgraded to Overweight from Neutral at Piper Sandler RLAY Relay Therapeutics $27.69 / -1.8 (-6.10%) 03/29/21 JMP Securities Relay Therapeutics price target lowered to $50 from $66 at JMP Securities 01/29/21 JPMorgan Relay Therapeutics price target raised to $52 from $36 at JPMorgan 12/15/20 H.C. Wainwright Relay Therapeutics price target raised to $57 from $54 at H.C. Wainwright 12/08/20 JMP Securities Relay Therapeutics initiated with an Outperform at JMP Securities ZBH Zimmer Biomet $171.99 / -0.575 (-0.33%) 05/11/21 JMP Securities Zimmer Biomet price target raised to $195 from $180 at JMP Securities 05/05/21 Truist Zimmer Biomet price target raised to $188 from $174 at Truist 05/05/21 Oppenheimer Zimmer Biomet price target raised to $195 from $185 at Oppenheimer 04/09/21 Northland Zimmer Biomet upgraded to Outperform from Market Perform at Northland WST West Pharmaceutical $333.76 / -0.36 (-0.11%) 11/09/20 KeyBanc West Pharmaceutical initiated with an Overweight at KeyBanc 10/13/20 Stephens West Pharmaceutical initiated with an Equal Weight at Stephens 07/21/20 BofA West Pharmaceutical upgraded to Buy on COVID-related tailwinds at BofA 07/21/20 BofA West Pharmaceutical upgraded to Buy from Neutral at BofA NVRO Nevro $155.00 / -1.15 (-0.74%) 05/06/21 Canaccord Nevro price target raised to $225 from $217 at Canaccord 04/05/21 Piper Sandler Nevro publication in JAMA Neurology helps add credibility, says Piper Sandler 02/25/21 Canaccord Nevro price target raised to $217 from $203 at Canaccord 02/02/21 Fly Intel: Top five analyst initiations HUM Humana $470.07 / +5.45 (+1.17%) 04/29/21 Oppenheimer Humana price target raised to $480 from $460 at Oppenheimer 04/29/21 Mizuho Humana price target raised to $480 from $462 at Mizuho 04/29/21 Citi Humana price target raised to $510 from $496 at Citi 04/16/21 Stephens Humana named a new Best Idea for 2021 at Stephens DHR Danaher $259.10 / +0.8 (+0.31%) 04/26/21 Barclays Danaher price target raised to $300 from $265 at Barclays 04/23/21 Jefferies Danaher price target raised to $290 from $270 at Jefferies 04/23/21 Baird Danaher price target raised to $270 from $249 at Baird 04/23/21 Wells Fargo Danaher price target raised to $280 from $260 at Wells Fargo ZBH WST TVTX SWAV RLAY QGEN PTCT PHG NVRO LLY JNJ JAZZ ITCI ISRG IMTX HUM FIXX DHR CCRN AVTR ADMS ADCT ZBH Zimmer Biomet $171.99 / -0.575 (-0.33%) 05/04/21 Zimmer Biomet sees FY21 adjusted EPS $7.60-$8.00, consensus $7.72 05/04/21 Zimmer Biomet reports Q1 adjusted EPS $1.71, consensus $1.53 05/03/21 Notable companies reporting before tomorrow's open WST West Pharmaceutical $333.76 / -0.36 (-0.11%) 04/29/21 West raises FY21 adjusted EPS view to $6.95-$7.10 from $6.00-$6.15 04/29/21 West Pharmaceutical reports Q1 adjusted EPS $2.05, consensus $1.43 02/18/21 West Pharmaceutical sees FY21 EPS $6.00-$6.15, consensus $5.12 02/18/21 West Pharmaceutical reports Q4 adjusted EPS $1.34, consensus $1.12 TVTX Travere Therapeutics $19.78 / -0.23 (-1.15%) 05/06/21 Travere Therapeutics reports Q1 EPS (96c), consensus (39c) 03/01/21 Travere Therapeutics reports Q4 adjusted EPS ($2.20), consensus (47c) 02/02/21 Travere Therapeutics achieves interim endpoint in Phase 3 DUPLEX study 01/11/21 Travere Therapeutics sees 2020 revenue $199M, consensus $198.61M SWAV ShockWave Medical $134.82 / -12.73 (-8.63%) 05/10/21 ShockWave Medical sees FY21 revenue of $195M-$205M, consensus $158.99M 05/10/21 ShockWave Medical reports Q1 EPS (68c), consensus (45c) 03/30/21 ShockWave Medical sees Q1 revenue $31M-$32M, consensus $24.9M 02/17/21 ShockWave Medical reports Q4 EPS (46c), consensus (42c) RLAY Relay Therapeutics $27.69 / -1.8 (-6.10%) 03/25/21 Relay Therapeutics reports Q4 net income $35.3M versus Q419 loss ($23.9M) 11/12/20 Relay Therapeutics reports Q3 EPS ($3.00) vs. ($5.53) last year QGEN Qiagen $46.90 / -0.75 (-1.57%) 05/03/21 Qiagen backs FY21 adjusted EPS $2.42-$2.46, consensus $2.49 05/03/21 Qiagen reports Q1 adjusted EPS 66c, consensus 63c 02/09/21 Qiagen backs FY21 EPS view $2.42-$2.46, consensus $2.40 02/09/21 Qiagen reports Q4 EPS 68c, consensus 65c PTCT PTC Therapeutics $38.88 / -1.34 (-3.33%) 05/04/21 PTC Therapeutics reports Q1 EPS ($1.83), consensus ($1.51) 02/25/21 PTC Therapeutics reports Q4 EPS ($1.08), consensus (94c) PHG Philips $56.39 / -1.016893 (-1.77%) 04/26/21 Philips reports Q1 adjusted EPS EUR 0.28 vs. EUR 0.14 last year 01/25/21 Philips reports Q4 adjusted EPS EUR 0.94 vs. EUR 0.83 last year NVRO Nevro $155.00 / -1.15 (-0.74%) 05/05/21 Nevro narrows FY21 revenue view to $440M-$450M from $430M-$450M 05/05/21 Nevro sees Q2 revenue $104M-$106M, consensus $101.14M 05/05/21 Nevro reports Q1 EPS (85c), consensus (84c) 02/24/21 Nevro sees FY21 revenue $430M-$450M, consensus $451.19M LLY Eli Lilly $194.82 / -0.75 (-0.38%) 04/27/21 Eli Lilly tightens FY21 EPS view to $7.80-$8.00 from $7.75-$8.40 04/27/21 Eli Lilly reports Q1 EPS $1.87, consensus $2.14 04/26/21 Notable companies reporting before tomorrow's open JNJ Johnson & Johnson $170.32 / +1.68 (+1.00%) 04/20/21 Johnson & Johnson raises FY21 adjusted EPS view to $9.30-$9.45 from $9.25-$9.45 04/20/21 Johnson & Johnson reports Q1 adjusted EPS 2.59, consensus $2.34 04/19/21 Notable companies reporting before tomorrow's open JAZZ Jazz Pharmaceuticals $176.02 / +1.35 (+0.77%) 05/04/21 Jazz Pharmaceuticals backs FY21 adjusted EPS view $15.65-$16.85 05/04/21 Jazz Pharmaceuticals reports Q1 EPS $3.92, consensus $3.71 02/23/21 Jazz Pharmaceuticals sees FY21 adjusted EPS $15.65-$16.85, consensus $16.78 02/23/21 Jazz Pharmaceuticals reports Q4 EPS $4.00, consensus $4.20 ITCI Intra-Cellular $35.97 / +1.01 (+2.89%) 05/10/21 Intra-Cellular reports Q1 EPS (65c), consensus (80c) 02/25/21 Intra-Cellular reports Q4 EPS (76c), consensus (85c) ISRG Intuitive Surgical $835.60 / -21.9 (-2.55%) 04/20/21 Intuitive Surgical reports Q1 EPS $3.52, consensus $2.63 04/20/21 Notable companies reporting after market close 01/21/21 Intuitive Surgical reports Q4 EPS $3.58, consensus $3.12 01/21/21 Notable companies reporting after market close IMTX Immatics $10.81 / -0.77 (-6.65%) 03/30/21 Immatics reports 2020 EPS (EUR4.77) vs. (EUR0.95) last year 12/02/20 Immatics reports Q3 revenue $9.1M, consensus $8.74M HUM Humana $470.07 / +5.45 (+1.17%) 04/28/21 Humana backs FY21 adjusted EPS view $21.25-$21.75, consensus $21.54 04/28/21 Humana reports Q1 adjusted EPS $7.67, consensus $7.07 04/27/21 Notable companies reporting before tomorrow's open FIXX Homology Medicines $6.39 / -0.13 (-1.99%) 05/06/21 Homology Medicines reports Q1 EPS (2c) , consensus (67c) 03/11/21 Homology Medicines reports Q4 EPS (62c), consensus (68c) DHR Danaher $259.10 / +0.8 (+0.31%) 04/22/21 Danaher sees 2021 non-GAAP core revenue growth in high-teens percent range 04/22/21 Danaher sees Q2 non-GAAP core revenue growth in mid-20 percent range 04/22/21 Danaher reports Q1 adjusted EPS $2.52, consensus $1.75 04/21/21 Notable companies reporting before tomorrow's open CCRN Cross Country Healthcare $17.16 / +0.26 (+1.54%) 05/05/21 Cross Country Healthcare sees Q2 adjusted EPS 37c-42c, consensus 15c 05/05/21 Cross Country Healthcare reports Q1 adjusted EPS 58c, consensus 34c 02/24/21 Cross Country Healthcare sees Q1 adjusted EPS 32c-37c, consensus 7c 02/24/21 Cross Country Healthcare reports Q4 adjusted EPS 19c, consensus 9c AVTR Avantor $30.48 / -0.725 (-2.32%) 04/28/21 Avantor reports Q1 adjusted EPS 35c, consensus 28c 02/03/21 Avantor reports Q4 adjusted EPS 29c, consensus 26c 01/11/21 Avantor reports preliminary Q4 revenue $1.79B, consensus $1.62B ADMS Adamas Pharmaceuticals $4.96 / -0.2 (-3.88%) 02/23/21 Adamas sees FY21 R&D expenses $5M-$10M 02/23/21 Adamas reports Q4 EPS (64c), consensus (51c) 01/13/21 Adamas Pharmaceuticals sees 2020 revenue $74.2M, consensus $75.15M 01/13/21 Adamas Pharmaceuticals sees Q4 revenue $20.8M, consensus $21.7M ADCT ADC Therapeutics $22.44 / -1.15 (-4.87%) 05/06/21 ADC Therapeutics reports Q1 adjusted EPS (74c), consensus (90c) 03/18/21 ADC Therapeutics reports Q4 adjusted EPS (82c), consensus (38c) 03/18/21 ADC Therapeutics reports Q4 EPS (73c), consensus (38c) 11/12/20 ADC Therapeutics reports Q3 EPS (58c), consensus (81c ) 07 Apr 25 Feb 12 Feb 06 Nov 24 Sep 11 Sep 20 Aug 16 Jul 17 Jun 21 May 15 May QGEN PHG NVRO LLY JNJ JAZZ DHR QGEN Qiagen $46.90 / -0.75 (-1.57%) 02/08/21 Quidel weighs combining with Qiagen, Bloomberg reports 02/08/21 Qiagen jumps after Bloomberg says Quidel made preliminary approach 02/08/21 Quidel weighs combining with Qiagen, Bloomberg reports PHG Philips $56.39 / -1.016893 (-1.77%) 01/05/21 Philips shortlists Asian suitors in home appliance unit sale, Bloomberg says NVRO Nevro $155.00 / -1.15 (-0.74%) 01/07/21 Nevro named a short idea, accused of fraud by Scorpion Capital LLY Eli Lilly $194.82 / -0.75 (-0.38%) 05/10/21 Eli Lilly to boost supply of Covid treatment in India, Reuters reports 05/05/21 Eli Lilly employees accuse executive of altering FDA documents, Reuters says 03/20/21 Still reasons to be hopeful about Lilly, Biogen Alzheimer's drugs, Barron's says 02/10/21 Eli Lilly won't try to claw back past pay from former CFO Smiley, WSJ reports JNJ Johnson & Johnson $170.32 / +1.68 (+1.00%) 05/06/21 Germany's Merkel opposed to vaccine patent waivers, Bloomberg reports 05/06/21 Merkel opposes plan to waive COVID vaccine patent protection, Bloomberg says 05/05/21 U.S. supports waiver of vaccine-patent protections at WTO, Bloomberg reports 05/02/21 Pfizer to send 4.5M COVID vaccine doses to South Africa, Axios reports JAZZ Jazz Pharmaceuticals $176.02 / +1.35 (+0.77%) 04/05/21 'Failure is the new winning' for Jazz Pharmaceuticals, FFJ says DHR Danaher $259.10 / +0.8 (+0.31%) 05/10/21 Renishaw struggling to attract takeover interest, Bloomberg reports 03/26/21 Danaher, Fortive interested in joint bid for Renishaw, Bloomberg reports 03/26/21 Danaher said to mull joint bid with Fortive for Renishaw, Bloomberg says ZBH SWAV QGEN PTCT PHG LLY JNJ JAZZ ISRG IMTX HUM FIXX CCRN ZBH Zimmer Biomet $171.99 / -0.575 (-0.33%) 02/05/21 Fly Intel: Pre-market Movers SWAV ShockWave Medical $134.82 / -12.73 (-8.63%) 02/17/21 Fly Intel: After-Hours Movers QGEN Qiagen $46.90 / -0.75 (-1.57%) 02/09/21 Fly Intel: After-Hours Movers 02/08/21 Fly Intel: Wall Street's top stories for Monday 11/11/20 Fly Intel: After-Hours Movers PTCT PTC Therapeutics $38.88 / -1.34 (-3.33%) 03/23/21 Ionis Pharmaceuticals slides as Wall Street digests HD program setback PHG Philips $56.39 / -1.016893 (-1.77%) 04/26/21 Fly Intel: Pre-market Movers 01/25/21 Fly Intel: Pre-market Movers 12/18/20 Fly Intel: Wall Street's top stories for Friday 12/18/20 Fly Intel: Wall Street's top stories at midday LLY Eli Lilly $194.82 / -0.75 (-0.38%) 04/27/21 Fly Intel: Wall Street's top stories for Tuesday 04/27/21 Fly Intel: Wall Street's top stories at midday 04/27/21 Fly Intel: Pre-market Movers 03/15/21 Fly Intel: Wall Street's top stories for Monday JNJ Johnson & Johnson $170.32 / +1.68 (+1.00%) 05/06/21 Moderna, Pfizer slip despite stronger results as U.S. backs vaccine IP waiver 05/05/21 Fly Intel: Wall Street's top stories for Wednesday 04/26/21 Fly Intel: Wall Street's top stories for Monday 04/26/21 Fly Intel: Wall Street's top stories at midday JAZZ Jazz Pharmaceuticals $176.02 / +1.35 (+0.77%) 02/18/21 Rising High: An exclusive talk with multinational cannabis company Clever Leaves 02/11/21 Rising High: An exclusive talk with biotech company Enveric Biosciences 02/03/21 Fly Intel: Wall Street's top stories for Wednesday 02/03/21 Fly Intel: Wall Street's top stories at midday ISRG Intuitive Surgical $835.60 / -21.9 (-2.55%) 04/20/21 Fly Intel: After-Hours Movers 01/21/21 Fly Intel: After-Hours Movers IMTX Immatics $10.81 / -0.77 (-6.65%) 03/17/21 Fly Intel: Wall Street's top stories for Wednesday 03/17/21 Fly Intel: Wall Street's top stories at midday 03/17/21 Fly Intel: Pre-market Movers HUM Humana $470.07 / +5.45 (+1.17%) 04/28/21 Fly Intel: Pre-market Movers 02/03/21 Fly Intel: Pre-market Movers 12/01/20 Fly Intel: What to watch in Salesforce's earnings report 11/14/20 Week in review: How Trump's policies moved stocks FIXX Homology Medicines $6.39 / -0.13 (-1.99%) 04/07/21 Fly Intel: Pre-market Movers 04/06/21 Fly Intel: After-Hours Movers 11/19/20 Fly Intel: After-Hours Movers CCRN Cross Country Healthcare $17.16 / +0.26 (+1.54%) 02/24/21 Fly Intel: After-Hours Movers 05/11/21 Diagnostics Virtual Conference 2021 05/12/21 CIO Future of Business Resilience Virtual Summit 05/12/21 Bank of America Merrill Lynch Virtual Healthcare Conference 05/25/21 MedTech Day Summit 05/25/21 Global Healthcare Virtual Conference 2021 07/21/21 Johnson & Johnson - JNJ 05/21/21 PDUFA Date for Loncastuximab Tesirine 08/12/21 PDFUA Date for Xywav 12/17/21 PDUFA Date for Lumateperone (CAPLYTA) 11:00 Today Avantor, Inc. 05/14/21 Zimmer Biomet Holdings, Inc. 05/14/21 Travere Therapeutics Inc 05/14/21 Cross Country Healthcare Inc. 05/19/21 Relay Therapeutics, Inc. 05/25/21 Nevro Corp. 06/02/21 Adamas Pharmaceuticals, Inc. 06/08/21 PTC Therapeutics, Inc. 06/17/21 Homology Medicines, Inc. 06/21/21 Intra-Cellular Therapies, Inc. 06/25/21 ShockWave Medical, Inc. 10/06/21 Humana ZBH TVTX RLAY LLY JNJ ISRG DHR ZBH Zimmer Biomet $171.99 / -0.575 (-0.33%) 12/29/20 Early notable gainers among liquid option names on December 29th TVTX Travere Therapeutics $19.78 / -0.23 (-1.15%) 11/19/20 One new option listing and one option delisting on November 19th RLAY Relay Therapeutics $27.69 / -1.8 (-6.10%) 01/20/21 Five new option listings on January 20th LLY Eli Lilly $194.82 / -0.75 (-0.38%) 05/05/21 Eli Lilly call volume above normal and directionally bullish 04/27/21 Unusually active option classes on open April 27th 03/11/21 Eli Lilly call volume above normal and directionally bullish 03/10/21 Eli Lilly call volume above normal and directionally bullish JNJ Johnson & Johnson $170.32 / +1.68 (+1.00%) 04/13/21 Unusually active option classes on open April 13th 04/01/21 Unusually active option classes on open April 1st 03/01/21 Unusually active option classes on open March 1st 01/26/21 Early notable gainers among liquid option names on January 26th ISRG Intuitive Surgical $835.60 / -21.9 (-2.55%) 04/21/21 Early notable gainers among liquid option names on April 21st 04/20/21 Intuitive Surgical options imply 6.3% move in share price post-earnings 11/12/20 Early notable gainers among liquid option names on November 12th DHR Danaher $259.10 / +0.8 (+0.31%) 04/13/21 Early notable gainers among liquid option names on April 13th 01/22/21 Early notable gainers among liquid option names on January 22nd

Over a week ago
Hot Stocks	Intuitive Surgical appoint Monica Reed to board of directors » 08:51 04/26/21 04/26 08:51 04/26/21 08:51 ISRG Intuitive Surgical $875.69 / +16.06 (+1.87%) Intuitive announced the… Intuitive announced the appointment of Dr. Monica Reed, a former AdventHealth executive, to its board of directors effective April 22, 2021. "Dr. Reed brings decades of leadership insight, experience, and accomplishments in hospital and health system administration that will complement our existing board," said Intuitive CEO Gary Guthart. "We look forward to her contributions as we continue to improve how we serve our surgeon, hospital, and healthcare system customers in this rapidly evolving healthcare environment." ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options ISRG Intuitive Surgical $875.69 / +16.06 (+1.87%) 04/20/21 Intuitive Surgical jumps about 4% above $842 after Q1 earnings 04/20/21 Intuitive Surgical sees 'similar quarterly patterns' to 2019 on procedure trends 04/20/21 Intuitive Surgical sees FY21 procedure growth of 22%-26% 01/21/21 Intuitive Surgical says overall procedure growth was 6% in Q4 ISRG Intuitive Surgical $875.69 / +16.06 (+1.87%) 04/21/21 SVB Leerink Intuitive Surgical price target raised to $860 from $825 at SVB Leerink 04/21/21 Wells Fargo Intuitive Surgical price target raised to $892 from $879 at Wells Fargo 04/21/21 Deutsche Bank Intuitive Surgical price target raised to $825 from $690 at Deutsche Bank 04/21/21 JPMorgan Intuitive Surgical price target raised to $900 from $840 at JPMorgan ISRG Intuitive Surgical $875.69 / +16.06 (+1.87%) 04/20/21 Intuitive Surgical reports Q1 EPS $3.52, consensus $2.63 04/20/21 Notable companies reporting after market close 01/21/21 Intuitive Surgical reports Q4 EPS $3.58, consensus $3.12 01/21/21 Notable companies reporting after market close ISRG Intuitive Surgical $875.69 / +16.06 (+1.87%) 04/20/21 Fly Intel: After-Hours Movers 01/21/21 Fly Intel: After-Hours Movers ISRG Intuitive Surgical $875.69 / +16.06 (+1.87%) 04/21/21 Early notable gainers among liquid option names on April 21st 04/20/21 Intuitive Surgical options imply 6.3% move in share price post-earnings 11/12/20 Early notable gainers among liquid option names on November 12th
Options	Early notable gainers among liquid option names on April 21st » 09:55 04/21/21 04/21 09:55 04/21/21 09:55 ISRG Intuitive Surgical $847.01 / +35.02 (+4.31%) , NCLH Norwegian Cruise Line $27.84 / +1.09 (+4.07%) , CTXS Citrix $141.96 / +3.84 (+2.78%) , DISH Dish $37.58 / +0.69 (+1.87%) , EW Edwards Lifesciences $92.83 / +3.21 (+3.58%) Notable gainers among… Notable gainers among liquid option names this morning include Intuitive Surgical (ISRG) $863.24 +50.95, Norwegian Cruise Line (NCLH) $28.38 +1.63, Citrix (CTXS) $143.56 +5.35, Dish Network (DISH) $38.21 +1.33, and Edwards Lifesciences (EW) $92.79 +3.16. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options NCLH ISRG EW DISH CTXS NCLH Norwegian Cruise Line $27.84 / +1.09 (+4.07%) 04/20/21 Norwegian Cruise Line announces Paid Volunteer Day starting in 2021 04/19/21 Royal Caribbean CEO says CDC, cruise industry engaged in 'constructive dialogue' 04/15/21 Norwegian Cruise Line asks CDC for reply on restarting cruises from U.S. ports 04/14/21 Norwegian Cruise Line donates $100,000 in gift cards to support Longshoremen ISRG Intuitive Surgical $847.01 / +35.02 (+4.31%) 04/20/21 Intuitive Surgical jumps about 4% above $842 after Q1 earnings 04/20/21 Intuitive Surgical sees 'similar quarterly patterns' to 2019 on procedure trends 04/20/21 Intuitive Surgical sees FY21 procedure growth of 22%-26% 01/21/21 Intuitive Surgical says overall procedure growth was 6% in Q4 EW Edwards Lifesciences $92.83 / +3.21 (+3.58%) 04/20/21 Edwards Lifesciences CEO says 'continued confidence' in 2021 outlook 01/31/21 Edwards Lifesciences announces new data from COMMENCE clinical trial 01/27/21 Edwards Lifesciences falls over 3% to $82 per share after Q4 earnings miss 01/27/21 Edwards Lifesciences sees COVID impact on sales in 'start of the year' DISH Dish $37.58 / +0.69 (+1.87%) 04/21/21 DISH and AWS form strategic collaboration for 5G services 04/07/21 Nokia security software selected by Dish to safeguard 5G network slices 04/06/21 Dish selects Allot to provide UPP on cloud-native OpenRAN-based 5G network 04/05/21 Dish selects Palo Alto Networks to help secure 5G network CTXS Citrix $141.96 / +3.84 (+2.78%) 04/19/21 Synnex signs distribution agreement with Citrix 03/16/21 Citrix announces multi-year partnership with Major League Baseball 01/19/21 Citrix raises quarterly dividend to 37c from 35c per share 01/19/21 Citrix to acquire Wrike for $2.25B in cash ISRG NCLH CTXS DISH EW ISRG Intuitive Surgical $847.01 / +35.02 (+4.31%) 04/21/21 SVB Leerink Intuitive Surgical price target raised to $860 from $825 at SVB Leerink 04/21/21 Wells Fargo Intuitive Surgical price target raised to $892 from $879 at Wells Fargo 04/21/21 Deutsche Bank Intuitive Surgical price target raised to $825 from $690 at Deutsche Bank 04/21/21 JPMorgan Intuitive Surgical price target raised to $900 from $840 at JPMorgan NCLH Norwegian Cruise Line $27.84 / +1.09 (+4.07%) 04/20/21 Goldman Sachs Norwegian Cruise Line upgraded to Buy from Neutral at Goldman Sachs 03/24/21 Stifel Cruiseline stock selloff 'unwarranted,' says Stifel 03/18/21 UBS Norwegian Cruise Line price target raised to $32 from $21 at UBS 03/16/21 JPMorgan Norwegian Cruise Line price target raised to $36 from $33 at JPMorgan CTXS Citrix $141.96 / +3.84 (+2.78%) 04/21/21 Fly Intel: Top five analyst upgrades 04/21/21 Jefferies Citrix upgraded to Buy from Hold at Jefferies 04/13/21 BofA Citrix reinstated with an Underperform at BofA 03/03/21 Citi Citrix assumed with a Buy at Citi DISH Dish $37.58 / +0.69 (+1.87%) 03/08/21 Citi Dish could pursue deal for TDS or U.S. Cellular for rural coverage, says Citi 02/25/21 Oppenheimer Verizon, AT&T downgraded to Perform on valuation at Oppenheimer 02/23/21 Fly Intel: Top five analyst downgrades 02/23/21 Pivotal Research Dish downgraded to Hold from Buy at Pivotal Research EW Edwards Lifesciences $92.83 / +3.21 (+3.58%) 04/21/21 Raymond James Edwards Lifesciences price target raised to $101 from $96 at Raymond James 04/21/21 Wells Fargo Edwards Lifesciences price target raised to $93 from $87 at Wells Fargo 04/21/21 Canaccord Edwards Lifesciences price target raised to $103 from $94 at Canaccord 04/21/21 Piper Sandler Edwards Lifesciences price target raised to $105 from $97 at Piper Sandler NCLH ISRG EW DISH CTXS NCLH Norwegian Cruise Line $27.84 / +1.09 (+4.07%) 02/25/21 Norwegian Cruise Line reports Q4 adjusted EPS ($2.33), consensus ($2.17) 02/24/21 Notable companies reporting before tomorrow's open 11/09/20 Norwegian Cruise Line reports Q3 adj. EPS ($2.35), consensus ($2.24) ISRG Intuitive Surgical $847.01 / +35.02 (+4.31%) 04/20/21 Intuitive Surgical reports Q1 EPS $3.52, consensus $2.63 04/20/21 Notable companies reporting after market close 01/21/21 Intuitive Surgical reports Q4 EPS $3.58, consensus $3.12 01/21/21 Notable companies reporting after market close EW Edwards Lifesciences $92.83 / +3.21 (+3.58%) 04/20/21 Edwards Lifesciences sees Q2 adjusted EPS 54c-60c, consensus 52c 04/20/21 Edwards Lifesciences raises FY21 adjusted EPS to $2.07-$2.27 from $2.00-$2.20 04/20/21 Edwards Lifesciences reports Q1 EPS 54c, consensus 47c DISH Dish $37.58 / +0.69 (+1.87%) 02/22/21 Dish reports Q4 EPS $1.24, consensus 75c 11/06/20 Dish reports Q3 EPS 86c, consensus 70c CTXS Citrix $141.96 / +3.84 (+2.78%) 01/19/21 Citrix sees FY21 adjusted EPS $6.20-$6.40, consensus $6.37 01/19/21 Citrix sees Q1 adjusted EPS $1.40-$1.45, consensus $1.47 01/19/21 Citrix reports Q4 adjusted EPS $1.46, consensus $1.33 10/22/20 Citrix sees FY21 EPS 6.20-$6.40, consensus $6.19 05 Mar 18 Nov 17 Jul 06 May NCLH DISH NCLH Norwegian Cruise Line $27.84 / +1.09 (+4.07%) 04/15/21 Blumenthal, Matsui urge CDC to maintain cruising restrictions, USA Today reports 04/10/21 Cruise Line stocks could sink, Barron's says 04/08/21 Florida sues U.S. government to force restart of cruises, WSJ reports 04/05/21 CDC responds to Norwegian plans, says phased restart needed, Bloomberg reports DISH Dish $37.58 / +0.69 (+1.87%) 11/18/20 Dish 'improperly' received $3.3B in spectrum discounts, FBN says 11/02/20 Dish offers services to DoD's proposed 5G network project, WSJ reports NCLH ISRG EW DISH NCLH Norwegian Cruise Line $27.84 / +1.09 (+4.07%) 04/08/21 Fly Intel: Wall Street's top stories for Thursday 03/24/21 Fly Intel: Wall Street's top stories for Wednesday 03/05/21 Fly Intel: Wall Street's top stories for Friday 03/05/21 Fly Intel: Wall Street's top stories at midday ISRG Intuitive Surgical $847.01 / +35.02 (+4.31%) 04/20/21 Fly Intel: After-Hours Movers 01/21/21 Fly Intel: After-Hours Movers EW Edwards Lifesciences $92.83 / +3.21 (+3.58%) 01/27/21 Fly Intel: After-Hours Movers 10/21/20 Fly Intel: After-Hours Movers DISH Dish $37.58 / +0.69 (+1.87%) 02/25/21 Analysts cut Verizon, AT&T ratings after companies spend big in FCC auction 02/25/21 Lowe's, Square upgrades among today's top calls on Wall Street 02/23/21 Starbucks upgrade, Kroger downgrade among today's top calls on Wall Street 02/22/21 Fly Intel: Pre-market Movers 04/29/21 Citrix - CTXS 04/22/21 Intuitive Surgical Inc 04/30/21 Dish Network Corporation 05/04/21 Edwards Lifesciences Corp. 05/20/21 Norwegian Cruise Line Holdings Ltd. 06/04/21 Citrix Systems Inc NCLH ISRG EW DISH NCLH Norwegian Cruise Line $27.84 / +1.09 (+4.07%) 04/07/21 Early notable gainers among liquid option names on April 7th 04/06/21 Norwegian Cruise Line call volume above normal and directionally bullish 04/05/21 Norwegian Cruise Line call volume above normal and directionally bullish 04/05/21 Early notable gainers among liquid option names on April 5th ISRG Intuitive Surgical $847.01 / +35.02 (+4.31%) 04/20/21 Intuitive Surgical options imply 6.3% move in share price post-earnings 11/12/20 Early notable gainers among liquid option names on November 12th EW Edwards Lifesciences $92.83 / +3.21 (+3.58%) 11/17/20 Early notable gainers among liquid option names on November 17th DISH Dish $37.58 / +0.69 (+1.87%) 03/03/21 Early notable gainers among liquid option names on March 3rd 02/25/21 Early notable gainers among liquid option names on February 25th 02/04/21 Dish Network put volume heavy and directionally bearish 12/22/20 Unusual call flow in option market yesterday
Recommendations	Intuitive Surgical price target raised to $860 from $825 at SVB Leerink » 08:34 04/21/21 04/21 08:34 04/21/21 08:34 ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) SVB Leerink analyst… SVB Leerink analyst Richard Newitter raised the firm's price target on Intuitive Surgical to $860 from $825 and keeps a Market Perform rating on the shares. Coming off a "solid" Q1 beat, the analysst continues to view Intuitive Surgical as a premium MedTech asset. However, he stays on the sidelines given an already big valuation premium, as he favors other MedTech growth stocks in his universe with equal/better growth profiles relative to their multiple, and as he sees less expensive ways to play a COVID recovery with better risk-reward. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Intuitive Surgical jumps about 4% above $842 after Q1 earnings 04/20/21 Intuitive Surgical sees 'similar quarterly patterns' to 2019 on procedure trends 04/20/21 Intuitive Surgical sees FY21 procedure growth of 22%-26% 01/21/21 Intuitive Surgical says overall procedure growth was 6% in Q4 ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/21/21 Wells Fargo Intuitive Surgical price target raised to $892 from $879 at Wells Fargo 04/21/21 Deutsche Bank Intuitive Surgical price target raised to $825 from $690 at Deutsche Bank 04/21/21 JPMorgan Intuitive Surgical price target raised to $900 from $840 at JPMorgan 04/21/21 Baird Baird upgrades Intuitive Surgical following guidance reinstatement ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Intuitive Surgical reports Q1 EPS $3.52, consensus $2.63 04/20/21 Notable companies reporting after market close 01/21/21 Intuitive Surgical reports Q4 EPS $3.58, consensus $3.12 01/21/21 Notable companies reporting after market close ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Fly Intel: After-Hours Movers 01/21/21 Fly Intel: After-Hours Movers 04/22/21 Intuitive Surgical Inc ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Intuitive Surgical options imply 6.3% move in share price post-earnings 11/12/20 Early notable gainers among liquid option names on November 12th
Recommendations	Intuitive Surgical price target raised to $892 from $879 at Wells Fargo » 08:06 04/21/21 04/21 08:06 04/21/21 08:06 ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) Wells Fargo analyst… Wells Fargo analyst Lawrence Biegelsen raised the firm's price target on Intuitive Surgical to $892 from $879 and keeps an Overweight rating on the shares following quarterly results. The analyst notes the company reported Q1 results that exceeded expectations and issued formal 2021 guidance for the first time. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Intuitive Surgical jumps about 4% above $842 after Q1 earnings 04/20/21 Intuitive Surgical sees 'similar quarterly patterns' to 2019 on procedure trends 04/20/21 Intuitive Surgical sees FY21 procedure growth of 22%-26% 01/21/21 Intuitive Surgical says overall procedure growth was 6% in Q4 ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/21/21 Deutsche Bank Intuitive Surgical price target raised to $825 from $690 at Deutsche Bank 04/21/21 JPMorgan Intuitive Surgical price target raised to $900 from $840 at JPMorgan 04/21/21 Baird Baird upgrades Intuitive Surgical following guidance reinstatement 04/21/21 Citi Intuitive Surgical price target raised to $939 from $862 at Citi ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Intuitive Surgical reports Q1 EPS $3.52, consensus $2.63 04/20/21 Notable companies reporting after market close 01/21/21 Intuitive Surgical reports Q4 EPS $3.58, consensus $3.12 01/21/21 Notable companies reporting after market close ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Fly Intel: After-Hours Movers 01/21/21 Fly Intel: After-Hours Movers 04/22/21 Intuitive Surgical Inc ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Intuitive Surgical options imply 6.3% move in share price post-earnings 11/12/20 Early notable gainers among liquid option names on November 12th

Recommendations	Intuitive Surgical price target raised to $825 from $690 at Deutsche Bank » 07:35 04/21/21 04/21 07:35 04/21/21 07:35 ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) Deutsche Bank analyst… Deutsche Bank analyst Imron Zafar raised the firm's price target on Intuitive Surgical to $825 from $690 and keeps a Hold rating on the shares. The company last night reported an "all-around high-quality" Q1, comfortably outperforming Street expectations across the board, Zafar tells investors in a research note. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Intuitive Surgical jumps about 4% above $842 after Q1 earnings 04/20/21 Intuitive Surgical sees 'similar quarterly patterns' to 2019 on procedure trends 04/20/21 Intuitive Surgical sees FY21 procedure growth of 22%-26% 01/21/21 Intuitive Surgical says overall procedure growth was 6% in Q4 ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/21/21 JPMorgan Intuitive Surgical price target raised to $900 from $840 at JPMorgan 04/21/21 Baird Baird upgrades Intuitive Surgical following guidance reinstatement 04/21/21 Citi Intuitive Surgical price target raised to $939 from $862 at Citi 04/21/21 Oppenheimer Intuitive Surgical upgraded to Perform from Underperform at Oppenheimer ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Intuitive Surgical reports Q1 EPS $3.52, consensus $2.63 04/20/21 Notable companies reporting after market close 01/21/21 Intuitive Surgical reports Q4 EPS $3.58, consensus $3.12 01/21/21 Notable companies reporting after market close ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Fly Intel: After-Hours Movers 01/21/21 Fly Intel: After-Hours Movers 04/22/21 Intuitive Surgical Inc ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Intuitive Surgical options imply 6.3% move in share price post-earnings 11/12/20 Early notable gainers among liquid option names on November 12th
Recommendations	Intuitive Surgical price target raised to $900 from $840 at JPMorgan » 07:25 04/21/21 04/21 07:25 04/21/21 07:25 ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) JPMorgan analyst Tycho… JPMorgan analyst Tycho Peterson raised the firm's price target on Intuitive Surgical to $900 from $840 and reiterates an Overweight rating on the shares. The company's "impressive" Q1 showcased an encouraging rebound in procedures and an improving capex outlook, Peterson tells investors in a research note. The analyst continues to view the rollout of flexible financing programs, combined with disciplined investments, as "smart moves to accelerate the post-pandemic recovery and grow the competitive moat ahead of new entrants." ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Intuitive Surgical jumps about 4% above $842 after Q1 earnings 04/20/21 Intuitive Surgical sees 'similar quarterly patterns' to 2019 on procedure trends 04/20/21 Intuitive Surgical sees FY21 procedure growth of 22%-26% 01/21/21 Intuitive Surgical says overall procedure growth was 6% in Q4 ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/21/21 Baird Baird upgrades Intuitive Surgical following guidance reinstatement 04/21/21 Citi Intuitive Surgical price target raised to $939 from $862 at Citi 04/21/21 Oppenheimer Intuitive Surgical upgraded to Perform from Underperform at Oppenheimer 04/21/21 Baird Intuitive Surgical upgraded to Outperform from Neutral at Baird ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Intuitive Surgical reports Q1 EPS $3.52, consensus $2.63 04/20/21 Notable companies reporting after market close 01/21/21 Intuitive Surgical reports Q4 EPS $3.58, consensus $3.12 01/21/21 Notable companies reporting after market close ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Fly Intel: After-Hours Movers 01/21/21 Fly Intel: After-Hours Movers 04/22/21 Intuitive Surgical Inc ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Intuitive Surgical options imply 6.3% move in share price post-earnings 11/12/20 Early notable gainers among liquid option names on November 12th
Upgrade	Baird upgrades Intuitive Surgical following guidance reinstatement » 06:50 04/21/21 04/21 06:50 04/21/21 06:50 ISRG Intuitive Surgical / + As reported previously,… As reported previously, Baird analyst Mike Polark upgraded Intuitive Surgical to Outperform from Neutral with a price target of $925, up from $825. The analyst noted the company "smashed" Q1 estimates and reinstated guidance for the first time since the pandemic started. He said forward comps are extraordinarily easy. volumes improved, and going forward he continues to believes the company is good is still innovating. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options ISRG Intuitive Surgical / + 04/20/21 Intuitive Surgical jumps about 4% above $842 after Q1 earnings 04/20/21 Intuitive Surgical sees 'similar quarterly patterns' to 2019 on procedure trends 04/20/21 Intuitive Surgical sees FY21 procedure growth of 22%-26% 01/21/21 Intuitive Surgical says overall procedure growth was 6% in Q4 ISRG Intuitive Surgical / + 04/21/21 Citi Intuitive Surgical price target raised to $939 from $862 at Citi 04/21/21 Oppenheimer Intuitive Surgical upgraded to Perform from Underperform at Oppenheimer 04/21/21 Baird Intuitive Surgical upgraded to Outperform from Neutral at Baird 04/21/21 Piper Sandler Intuitive Surgical price target raised to $840 from $735 at Piper Sandler ISRG Intuitive Surgical / + 04/20/21 Intuitive Surgical reports Q1 EPS $3.52, consensus $2.63 04/20/21 Notable companies reporting after market close 01/21/21 Intuitive Surgical reports Q4 EPS $3.58, consensus $3.12 01/21/21 Notable companies reporting after market close ISRG Intuitive Surgical / + 04/20/21 Fly Intel: After-Hours Movers 01/21/21 Fly Intel: After-Hours Movers 04/22/21 Intuitive Surgical Inc ISRG Intuitive Surgical / + 04/20/21 Intuitive Surgical options imply 6.3% move in share price post-earnings 11/12/20 Early notable gainers among liquid option names on November 12th
Recommendations	Intuitive Surgical price target raised to $939 from $862 at Citi » 06:31 04/21/21 04/21 06:31 04/21/21 06:31 ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) Citi analyst Joanne… Citi analyst Joanne Wuensch raised the firm's price target on Intuitive Surgical to $939 from $862 and reiterates a Buy rating on the shares. The company's Q1 was better than expected, reflecting a recovery in procedure volumes and daVinci placements, Wuensch tells investors in a research note. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Intuitive Surgical jumps about 4% above $842 after Q1 earnings 04/20/21 Intuitive Surgical sees 'similar quarterly patterns' to 2019 on procedure trends 04/20/21 Intuitive Surgical sees FY21 procedure growth of 22%-26% 01/21/21 Intuitive Surgical says overall procedure growth was 6% in Q4 ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/21/21 Oppenheimer Intuitive Surgical upgraded to Perform from Underperform at Oppenheimer 04/21/21 Baird Intuitive Surgical upgraded to Outperform from Neutral at Baird 04/21/21 Piper Sandler Intuitive Surgical price target raised to $840 from $735 at Piper Sandler 04/05/21 Evercore ISI Evercore upgrades Edwards to Outperform ahead of its 'best pipeline cycle' ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Intuitive Surgical reports Q1 EPS $3.52, consensus $2.63 04/20/21 Notable companies reporting after market close 01/21/21 Intuitive Surgical reports Q4 EPS $3.58, consensus $3.12 01/21/21 Notable companies reporting after market close ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Fly Intel: After-Hours Movers 01/21/21 Fly Intel: After-Hours Movers 04/22/21 Intuitive Surgical Inc ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Intuitive Surgical options imply 6.3% move in share price post-earnings 11/12/20 Early notable gainers among liquid option names on November 12th
Upgrade	Intuitive Surgical upgraded to Perform from Underperform at Oppenheimer » 06:12 04/21/21 04/21 06:12 04/21/21 06:12 ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) Oppenheimer analyst Suraj… Oppenheimer analyst Suraj Kalia upgraded Intuitive Surgical to Perform from Underperform without a price target, citing the company's "strong" Q1 and outlook. Fiscal 2021 procedure growth guidance was introduced at 22%-26%, well ahead of Street's 18% estimate, on U.S. general surgery and earlier-stage outside the U.S. markets, Kalia tells investors in a research note. The analyst now sees a better post-Covid outlook for Intuitive Surgical. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Intuitive Surgical jumps about 4% above $842 after Q1 earnings 04/20/21 Intuitive Surgical sees 'similar quarterly patterns' to 2019 on procedure trends 04/20/21 Intuitive Surgical sees FY21 procedure growth of 22%-26% 01/21/21 Intuitive Surgical says overall procedure growth was 6% in Q4 ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/21/21 Baird Intuitive Surgical upgraded to Outperform from Neutral at Baird 04/21/21 Piper Sandler Intuitive Surgical price target raised to $840 from $735 at Piper Sandler 04/05/21 Evercore ISI Evercore upgrades Edwards to Outperform ahead of its 'best pipeline cycle' 04/01/21 Fly Intel: Top five analyst initiations ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Intuitive Surgical reports Q1 EPS $3.52, consensus $2.63 04/20/21 Notable companies reporting after market close 01/21/21 Intuitive Surgical reports Q4 EPS $3.58, consensus $3.12 01/21/21 Notable companies reporting after market close ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Fly Intel: After-Hours Movers 01/21/21 Fly Intel: After-Hours Movers 04/22/21 Intuitive Surgical Inc ISRG Intuitive Surgical $809.85 / -0.91 (-0.11%) 04/20/21 Intuitive Surgical options imply 6.3% move in share price post-earnings 11/12/20 Early notable gainers among liquid option names on November 12th

On The Fly

News and insights, exclusive to thefly.com

13:14	Notable companies reporting after market close»
09:53	Fly Intel: Top five analyst initiations»
09:53	Fly Intel: Top five analyst downgrades»
09:53	Fly Intel: Top five analyst upgrades»
20:25	Notable companies reporting before tomorrow's open»

View all On The Fly Stories »

Upcoming
Events (10)

SUP	Superior Industries - SUP
NPTN	NeoPhotonics - NPTN
ARCH	Arch Resources - ARCH
	8th Annual Media & Communications Virtual Summit
	SAWC Spring Virtual Conference 2021
	Business Services 1:1 Virtual Day
	ShopTalk Meetup for Women
C	39th Annual Monetary and Trade Virtual Conference
	Household Financial Well-Being in the Southeast
ACRE ...	JMP Securities' Virtual Insurance Week

View all of today’s events »

Today’s
Syndicate (3)

ACT	IPO
AJG	Secondary
BRT	Secondary

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial